Literature DB >> 11092199

Interstitial lung disease in polymyositis and dermatomyositis.

M Hirakata1, S Nagai.   

Abstract

Interstitial lung disease (ILD) is common in patients with polymyositis (PM) and dermatomyositis (DM), and is a major cause of morbidity. Although its cause is unknown, it is known to be closely associated with autoimmune disorders. Its manifestation has been found to be quite heterogeneous, as demonstrated by the differences among PM/DM patients in their immunologic profiles and histopathologic findings, which suggest variations in immunopathogenetic mechanisms. We review the clinicopathologic and immunologic findings in ILD associated with PM/DM, and discuss recent advances in classification, autoantibodies, and treatment. The most critical issues are to clarify the immunopathogenesis of severe forms of ILD, such as rapidly progressive ILD associated with amyopathic DM, and to establish the most appropriate therapy.

Entities:  

Mesh:

Year:  2000        PMID: 11092199     DOI: 10.1097/00002281-200011000-00005

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  22 in total

1.  Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications.

Authors:  S Zhang; X Shu; X Tian; F Chen; X Lu; G Wang
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 2.  Exercise: an important component of treatment in the idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

3.  Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases.

Authors:  Kuang-Hui Yu; Yeong-Jian Jan Wu; Chang-Fu Kuo; Lai-Chu See; Yu-Ming Shen; Hsiao-Chun Chang; Shue-Fen Luo; Huei-Huang Ho; I-Jung Chen
Journal:  Clin Rheumatol       Date:  2011-09-14       Impact factor: 2.980

4.  Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.

Authors:  Shuang Ye; Xiao-xiang Chen; Xiao-ye Lu; Mei-fang Wu; Yun Deng; Wen-qun Huang; Qiang Guo; Cheng-de Yang; Yue-ying Gu; Chun-de Bao; Shun-le Chen
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

5.  Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.

Authors:  G J D Hengstman; H J ter Laak; W T M Vree Egberts; I E Lundberg; H M Moutsopoulos; J Vencovsky; A Doria; M Mosca; W J van Venrooij; B G M van Engelen
Journal:  Ann Rheum Dis       Date:  2006-05-05       Impact factor: 19.103

6.  Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis.

Authors:  M G Danieli; G Malcangi; C Palmieri; F Logullo; A Salvi; M Piani; G Danieli
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

7.  The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors:  Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

8.  Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.

Authors:  Yuzo Suzuki; Hiroshi Hayakawa; Seiichi Miwa; Masahiro Shirai; Masato Fujii; Hitoshi Gemma; Takafumi Suda; Kingo Chida
Journal:  Lung       Date:  2009-04-22       Impact factor: 2.584

9.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I-Jung Chen; Yeong-Jian Jan Wu; Cho-Wei Lin; Kang-Wei Fan; Shue-Fen Luo; Huei-Huang Ho; Lieh-Bang Liou; Wen-Pin Tsai; Ji-Yih Chen; Chung-Han Yang; Chang-Fu Kuo; Kuang-Hui Yu
Journal:  Clin Rheumatol       Date:  2009-02-27       Impact factor: 2.980

Review 10.  Idiopathic inflammatory myopathy: autoantibody update.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.